Advancing GLP-1 treatments, insulin and large-volume injections with RTU cartridges from SCHOTT

Published: 20-Nov-2023

SCHOTT Pharma announces the availability of its ready-to-use (RTU) cartridges for clinical and commercial filling

The small volume cartridges are particularly suitable for administering insulin and GLP-1 drugs, which are used to treat diabetes and obesity, whereas the large volume cartridges are suitable to store high-value biologics to treat cancer or Parkinson's disease, for example.

As a RTU solution, the containers are washed, depyrogenated, siliconised and steam sterilised, which allows CDMOs and pharma companies to immediately start the filling process without having to handle the preparatory steps themselves.

“We see ourselves as a partner to the pharma industry and our RTU portfolio reduces the workload for drug manufacturers as we’re taking care of time- and cost-intensive process steps ourselves,” said Andreas Reisse, CEO of SCHOTT Pharma.

RTU solutions are already established to fill smaller drug charges for clinical trials and are now increasingly used in commercial drug production.

The company offers a complete RTU portfolio including cartridges, syringes and vials, and is ready to supply large quantities for human use.

Made of high-quality borosilicate glass, SCHOTT Pharma’s RTU cartridges allow for improved drug stability thanks to an optimised leachable behaviour of the glass and prequalified components, such as combi-seals and plungers.

“With our RTU cartridges, we’re able to help pharma companies, CDMOs and start-ups alike to maintain a short time to market, while increasing processing and output efficiency,” explains Elisa Wiesner, Global Product Manager for bulk and sterile cartridges at SCHOTT Pharma.

“Subsequently, the drugs can reach the patients in a timely and safe manner.”

The RTU cartridges known as cartriQ are compatible with hand-held injection devices such as pens and autoinjectors, while the cartriQ Large Volume products are ideally suited for wearable large-volume injectors (LVI).

Like this story? Subscribe to Manufacturing Chemist magazine for the latest news, updates and expert-written articles from the global pharmaceutical and biopharma sectors. For more information click here.

The prequalified device fit supports the shift from hospital to homecare, whereby patients can safely inject drugs themselves in the comfort of their homes.

As part of the SCHOTT iQ platform, which also includes RTU syringes and vials, the RTU cartridges are delivered in an industry standard nest and tub and remain nested throughout the filling process.

This eliminates glass-to-glass contact and allows pharma companies full flexibility when filling different medications in different containers on one filling line.

You may also like